Compare AbCellera Biologics Inc (ABCL) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Msci Inc — how do they compare? AbCellera Biologics Inc trades at $8.98 (market cap $2.99B), while Msci Inc trades at $562 (market cap $40.84B). The key difference: Msci Inc is far larger — about 13.7× AbCellera Biologics Inc's market cap, and Msci Inc pays a 1.46% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MSCI | |
|---|---|---|
Market Cap | $2.99B | $40.84B |
Sector | Health | Financials |
52-Week High | $9.76 | $643.83 |
52-Week Low | $2.78 | $511.84 |
Enterprise Value | $2.58B | $47.00B |
Dividend Yield | — | 1.46% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
